US clears Sanofi’s ‘follow-on’ insulin Admelog
The US Food and Drug Administration has cleared Sanofi’s Admelog, the first follow-on biologic version of Eli Lilly’s Humalog, to manage mealtime blood sugar levels in people with diabetes.
Read More
Tag: follow-on
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
